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Abstract 
BACKGROUND: Diabetic peripheral neuropathy (DPN) means the presence of symptoms and/or signs of 
peripheral nerve damage that occur to people with diabetes, excluding all other causes of neuropathy. Chronic 
hyperglycaemia leads to increased secretion of tumour necrotic factor-alpha (TNF-α), with the development of 
micro and macroangiopathy, damage to nerve fibres and local demyelination. 
AIM: To determine the role of inflammation in the peripheral nerve damage process concerning people suffering 
from type II diabetes mellitus. 
MATERIAL AND METHODS: The study included a total of 80 subjects, men and women, divided into two groups: 
an examined group (n = 50) consisting of subjects with DPN at the age from 30 to 80 years and a control group (n 
= 30) of healthy subjects aged from 18 to 45. In the investigated group, a neurological examination was performed 
using the Diabetic Neuropathy Symptoms (DNS) Score and Electroneurography. All the subjects had the blood 
plasma concentration of TNF-α by ELISA technique. 
RESULTS: The average value of TNF-α in the test group was 8.24 ± 2.899 pg/ml, while the control group was 
4.36 ± 2.622 pg/ml (p < 0.0001). The average value of TNF-α was correlated with the achieved DNS score in the 
investigated group (p = 0.005). Concerning the linear association of the concentration of TNF-α with the peripheral 
nerve velocity in the investigated group, no statistical significance was detected. 
CONCLUSION: Inflammation can play a role in the pathogenesis of diabetic autonomic neuropathy and cranial 
neuritis. 
 
 
 
 
 
Introduction 
 
Diabetic peripheral neuropathy (DPN) is the 
most common microvascular complication in type I 
and type II diabetes mellitus, with an average in 30% 
of cases is with clinical manifestation as a painful 
neuropathy [1]. DPN means the presence of 
symptoms and/or signs of peripheral nerve damage 
that occur to people with diabetes, excluding all other 
causes of neuropathy. In the first years of diabetes, 
neuropathies develop about 5-10% of the patients, 
and after 20 years the duration of diabetes is thought 
to be about 60-70% of the patients develop some of 
the forms of diabetic peripheral neuropathy [2]. People 
who suffer from diabetic sensory neuropathy have a 
25% greater risk of developing an ulcer on the feet 
and amputation of the limbs. The three-year survival 
of people with diabetic neuropathy is about 20% lower 
compared to people suffering from diabetes mellitus 
but have no peripheral neuropathy [3].  
TNF-α (also known as cachectin) is a pro-
inflammatory cytokine that plays a major role in the 
emergence of diabetic neuropathy; unlike other 
microvascular complications such as retinopathy or 
nephropathy (where the dominant role is played by IL-
6 and CRP). In animal models, the role of TNF-α in 
the peripheral and central sensitisation mechanisms 
has been proven, and hence the occurrence of 
neuropathic pain [4]. Human TNF-α is synthesised as 
a 26 kDa type II transmembrane protein consisting of 
35 amino acids in the cytoplasmic domain, 21 amino 
acids in the transmembrane segment and 177 amino 
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acids in the extracellular domain. In the extracellular 
domain, the human TNF-α possesses amino acid 
sequences that are 97% identical to those of rhesus 
monkeys; 71-92% identical to the amino acids 
detected in TNF-α in cows, dogs, horses, mice, rats. It 
creates various types of cells: immune, epithelial, 
endothelial, and tumor cells. 
Chronic hyperglycaemia leads to the 
stimulation of macrophages, such as cells that 
dominantly secrete TNF-α and increased secretion of 
this cytokine, by developing micro and 
macroangiopathy. TNF-α increases the expression of 
endothelial cell adhesion molecules and thus 
accelerates the process of atherosclerosis [5]. The 
increased production of TNF-α secondary to 
hyperglycemia is a factor of exacerbation of insulin 
resistance in ill-controlled diabetes. The influence of 
TNF-α on Schwann cells should also be neglected, 
which explains local demyelination in the pathological 
process of peripheral neuropathy. 
The aim of the study was to determine the 
role of inflammation in the process of peripheral nerve 
damage concerning people suffering from type II 
diabetes mellitus. 
 
 
Material and Methods 
 
A total of 80 examinees, men and women, 
were divided into two groups: a study group (n = 50) 
consisting of subjects with the symptomatology of 
DPN, aged 30 to 80 years, and a control group (n = 
30) composed of healthy subjects, aged 18 to 45 
years. Criteria for inclusion in the research were: 
respondents with diagnosed type II diabetes mellitus, 
lasting one to 40 years; on regular therapy with oral 
antidiabetics and / or insulin, with symptoms and signs 
of DPN. Criteria for exclusion from the study were: 
pre-diagnosed diabetic retinopathy and nephropathy; 
ischemic/haemorrhagic stroke or acute myocardial 
infarction over the past 12 months; acute and/or 
chronic skin infection, respiratory and gastrointestinal 
infection, known malignancy and autoimmune 
diseases, where higher plasma concentrations of 
TNF-α and diabetic foot or gangrene can be expected. 
In the respondents from the investigated 
group (n = 50) clinical and neurological examination 
was first performed to determine the clinical type of 
DPN. To assess the severity of the clinical picture in 
our study, we used the Diabetic Neuropathy Symptom 
score-DNS, which assessed the following symptoms: 
pain, stiffness, tingling and the presence of ataxia. An 
objective electrophysiological assessment of the 
degree of damage to the peripheral nerves was made 
using electroneurography, which included the 
following peripheral nerves: n. medianus, n. ulnaris, n. 
peroneus profundus and n. suralis. 
Subsequently, a sample of blood from the 
vein was taken for all subjects to determine the 
concentration of a TNF-α. Blood samples were first 
centrifuged to separate the blood plasma from the 
cellular elements, and then the blood plasma samples 
(about 1-2 ml) were frozen at -70°C. The 
concentration of the TNF-α was determined by 
the enzyme-linked immunosorbent assay (ELISA) 
technique. Anti-TNF-α antibodies that are absorbed in 
the wells bind to TNF-α which is present in the sample 
or standards. Subsequently, the addition of secondary 
biotinized anti-TNF-α antibodies that bind to TNF-α 
which is bound to the primary antibody. After 
incubation, unbound biotinised anti-TNF-α antibodies 
are removed by rinsing. The next step involves the 
addition of horseradish peroxidase (HRP) that is 
conjugated with streptavidin and which binds to biotin-
conjugated anti-TNF-α antibodies.  
After incubation, the unbound streptavidin 
HRP is removed by rinsing and a substrate solution 
for peroxidase, tetramethylbenzidine (TMB), which 
forms a colored product and whose coloring is 
proportional to the concentration of TNF-α in the 
sample or standard solution, is added. The reaction is 
stopped with 1 M phosphoric acid and the absorbance 
is measured at 450 nm. A standard curve of 7 
standard solutions of TNF-α is formed.  
For the analysis of the material were used the 
following statistical methods: frequency, percentage, 
contingency table, 
2
-Chi square test, Fisher Exact 
Test (FET), p index of statistical significance, mean 
value, standard deviation, Student t-test, Fisher F-test 
and Pearson correlation coefficient r. 
 
 
Results 
 
Based on the clinical presentation of DPN, the 
subjects (n = 50) were divided into 4 categories: 11 
(22%) with a clinical picture of sensory neuropathy, 29 
(58%) were with senso-motor neuropathy; 4 (8%) with 
cranial mononeuritis and 6 (12%) with dominant 
autonomic symptomatology (autonomic neuropathy). 
Regarding the achieved number of points on the DNS 
scale, the respondents were divided into four groups: 
with 1 point were 13 respondents, of which 6 (12%) 
were men, and 7 (14%) were women. With 2 points, 
there were 17 respondents, 7 (14%) men, 10 (20%) 
women. With 3 points on the DNS score were 10 
respondents and 6 (12%) were men, and 4 (8%) were 
women. Ten respondents had 4 points on the DNS 
score with equal representation of men and women, 
respectively 5 (10%). 
The average age of respondents in the study 
group was 65.5 years, while healthy subjects were 
33.6 years old. The control group was composed of 
younger respondents because of the lower likelihood 
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of other chronic illnesses, which would give higher 
values of the investigated pro-inflammatory marker 
TNF-α. Based on the statistical analysis, it is noted 
that there is a statistically significant difference 
between the average age of subjects in the 
investigated and control group at the level p < 0.0001. 
 The average TNF-α blood plasma sample 
of the test group (n = 50) was 8.24 ± 2.899 pg/ml, 
while the control group (n = 30) was 4.36 ± 2.622 
pg/ml (p < 0.0001). The average plasma TNF-α 
sample in the subjects from the test group (n = 50) 
was 8.24 pg/ml, 8.05 pg/ml for men and 8.40 pg/ml for 
women. The conducted statistical analyses showed 
that there was no statistically significant difference 
between the average values of TNF-α in men and 
women (p = 0.671). The average value of TNF-a does 
not depend on gender. 
The average plasma concentration of TNF-α 
considering subjects with diabetic senso-motor 
peripheral neuropathy (n = 29) was 8.08 pg/ml, in 
subjects with diabetic sensory peripheral neuropathy 
(n = 11) was 6.81 pg/ml. The average TNF-α 
concentration in subjects with diabetic autonomic 
neuropathy (n = 6) was 11.2 pg/ml, while those with 
cranial mononeuritis (n = 4) was 8.85 pg/ml.  
The average value of TNF-α was correlated 
with the achieved DNS score in the examined group 
(p = 0.005). The results are shown in Table 1. 
Table 1: The average value of TNF-α dependence on DNS score 
in the examined group (n = 50) and statistical significance 
DNS scorе 
TNF-α (pg/ml) 
Average value ± S.D. 
n F (p) 
1 6.138 ± 1.975 13 
4.84 
 
P = 0.005 
2 8.352 ± 3.058 17 
3 8.83 ± 3.27 10 
4 10.18 ± 1.503 10 
F-Fisher test; S.D. standard deviation; p-index of statistical significance. 
 
Regarding the DNS score connection, the 
score with the DPN type was found a statistically 
significant difference at the level p = 0.0244. 
Respondents with autonomic neuropathy and cranial 
neuritis had higher scores on the DNS scale. This is 
shown in Table 2.  
Table 2: Distribution by clinical type of diabetic peripheral 
neuropathy depending on the DNS score in the examined 
group (n = 50) and statistical significance 
DPN type 
DNS scorе 
FET p 
1 2 3 4 
Sensomotor 6 (12 %) 11 (22 %) 8 (16 %) 4 (8 %) 
P = 0.0244 
Sensory 5 (10 %) 5 (10 %) 1 (2 %) 0 (0 %) 
Autonomous 0 (0 %) 1 (2 %) 1 (2%) 4 (8 %) 
Cranial mononeuritis 2 (4 %) 0 (0 %) 0 (0 %) 2 (4 %) 
FET-Fisher Exact Test; p-index of statistical significance. 
 
Regarding the linear association of the 
concentration of TNF-α with the peripheral nerve 
velocity in the examined group, no statistical 
significance was found of the Pearson correlation 
coefficient r in any of the motor and sensory nerves 
conduction velocity. 
Table 3: Correlation between TNF-α and the rates of nerve 
testing in the examined group (n = 50) and statistical 
significance 
 
Pearson correlation 
coefficient r 
Relation t (p) 
n. medianus -0.103 TNF-α = 9.699 – 0.030 -0.721 p = 0.474 
n. ulnaris -0.1 TNF-α = 10.125 – 3.841 -0.699 p = 0.488 
n. peroneus -0.178 TNF-α= 10.103 – 4.887 -1.257 p = 0.215 
n. medianus 0.009 TNF-α = 8.182 + 1.419 6.559 p = 0.948 
n. ulnaris -0.093 TNF-α = 8.734 – 0.0129 0.653 p = 0.516 
n. suralis 0.058 TNF-α = 8.044 + 9.932 0.405 p = 0.687 
t-Student test; p-index of statistical significance. 
 
 
 
Discussion 
 
Diabetic peripheral neuropathy is the most 
common microvascular complication in diabetes 
mellitus. There are many different mechanisms 
involved in peripheral nerve damage in diabetic 
peripheral neuropathy, of which the key role in 
oxidative stress, inflammation and mitochondrial 
dysfunction [6]. Diabetes causes functional deficiency 
of nitric monoxide, activation of alternative metabolic 
pathways, accumulation of end-products of glycation, 
oxidative stress and inflammation, by activating 
inflammatory molecules. People with diabetes mellitus 
have an increased expression of pro-inflammatory 
cytokines such as C-reactive protein, TNF-α and IL-6. 
Chronic hyperglycemia leads to infiltration of cytokines 
into the vascular tissue and thus reduces the ability to 
repair.  
Obesity increases the risk of developing 
neuropathy precisely because the fat tissue has 
increased expression of TNF-α, which in turn is 
involved in the mechanisms of insulin resistance. 
There is also a positive correlation between the 
increased plasma concentration of TNF-α and the 
number of macrophages with the progression of 
diabetic peripheral neuropathy [7].  
In 2009, Herder et al. investigated the 
association of inflammation with diabetic peripheral 
neuropathy (by analysing 10 inflammatory markers of 
a total of 227 subjects who had type 2 diabetes 
mellitus). In this study, a high degree of association 
was found between CRP and IL-6 concentrations in 
people suffering from diabetic peripheral neuropathy 
[8]. 
In another study, an inverse association was 
found between the level of TNF-α and the nerves 
conduction velocities of n. suralis, n. medianus, and n. 
ulnaris, by analyzing the inflammatory marker in 
people who did not suffer from diabetic peripheral 
neuropathy and those who had undergone less than 
or more than 8 years of diagnosing diabetic 
neuropathy. Respondents who had diabetic 
neuropathy had higher serum TNF-α concentrations 
compared to others, with an upward trend in the 
duration of the disease [9]. 
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In our study, subjects with diabetic peripheral 
neuropathy had higher concentrations of TNF-α in 
blood plasma related to healthy subjects, or 
individuals without diabetic neuropathy. This confirms 
the finding of numerous research studies where the 
role of TNF-α in the pathogenesis of DPN was 
examined [10], [11].  
For a clinical assessment of the severity of 
DPN in our research, we used the DNS score as a 
simplified system for the diagnosis of distal diabetic 
neuropathy. Regarding the impact of the clinical type 
of diabetic peripheral neuropathy on the average 
value of TNF-α, in our study, higher TNF-α 
concentrations in the blood plasma sample had 
subjects in whom damage of the autonomic nervous 
system and cranial nerves were clinically dominant. 
The highest percentage of subjects diagnosed with 
diabetic autonomic neuropathy and cranial 
mononeuritis had a maximum number of points on the 
DNS score. The correlation between the levels of 
TNF-α with the severity of DPN has been proven in 
numerous research studies [7], [12], [13].  
When it comes to the association of TNF-α 
concentration in blood plasma with the motor and 
sensory conduction velocities the examined nerves, 
no correlation was found in any of our motor and 
sensory implementation rates. That is, the increased 
plasma concentration of TNF-α as pro-inflammatory 
cytokine does not affect the neuropathic 
characteristics of the peripheral nerves. Regarding the 
link of the DNS score with the motor and sensory 
velocities of conducting the examined nerves, no 
positive correlation between these two parameters 
was found in our research study, that is, the severity 
of the clinical picture in subjects with diabetic 
peripheral neuropathy does not depend on the 
conduction velocities of the examined peripheral 
nerves. 
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